title: Thromboxane A2 receptor characterization in human astrocytoma cells and rabbit platelets by a new thromboxane antagonist, [3H]ONO NT-126.
abstract: Thromboxane A2 receptors of human astrocytoma cells and rabbit platelets were characterized by a binding of a new potent and selective thromboxane A2 antagonist, [3H]ONO NT-126. [3H]ONO NT-126 bound with a high affinity to membranes derived from astrocytoma cells and platelets. In astrocytoma cells, the nonspecific binding determined by 1 microM S-145 was observed in high percentage to total binding. Scatchard plots of both membranes were linear, expressing a single binding site with the Kd of 0.17 nM and Bmax of 46.4 fmol/mg protein in astrocytoma cell membranes and with the Kd of 0.28 nM and Bmax of 1585 fmol/mg protein in platelet membranes, respectively. [3H]ONO NT-126 binding was displaced most potently by ONO NT-126 among other thromboxane A2 analogues. [3H]ONO NT-126 binding was displaced by ONO NT-126, S-145, SQ29548, STA2 and U46619 with Ki values (nM) of 0.21, 1.14, 7.05, 23.5 and 235 in astrocytoma cell membranes and 0.23, 5.55, 259, 9.25 and 43.7 in platelet membranes, respectively. The characteristics of TXA2 receptors apparently differ in rabbit platelets and human astrocytoma cells.
authors.affiliation: Department of Pharmacology, Fukushima Medical College, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Takano
authors.forename: H
authors.initials: H
authors.lastname: Ishimoto
authors.forename: N
authors.initials: N
authors.lastname: Nakahata
authors.forename: H
authors.initials: H
authors.lastname: Nakanishi
mesh_terms: D000818:Animals; D001254:Astrocytoma / Q000378:metabolism*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D002462:Cell Membrane / Q000378:metabolism; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D005260:Female; D019204:GTP-Binding Proteins / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009423:Nervous System Neoplasms / Q000378:metabolism*; D011817:Rabbits; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors / Q000187:drug effects*; D017482:Receptors, Thromboxane; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured / Q000378:metabolism; D010738:Type C Phospholipases / Q000378:metabolism; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
chemical_list: D001643:Bridged Bicyclo Compounds; D005229:Fatty Acids, Monounsaturated; D005231:Fatty Acids, Unsaturated; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D010566:Virulence Factors, Bordetella; C056566:S 145; C067519:ONO-NT 125; D013928:Thromboxane A2; D010738:Type C Phospholipases; D019204:GTP-Binding Proteins